Appointments: Senior Hires At IGM, Cell Medica, Mologen, Navitor, Tenaya, Oncobiologics, Provention Bio And Centrexion
New CEOs have been appointed at Cell Medica, Mologen, Navitor Pharmaceuticals, Tenaya Therapeutics and Oncobiologics, while a new CMO has been recruited to IGM Biosciences, a vice president of clinical development at Provention Bio and a CFO at Centrexion Therapeutics.
You may also be interested in...
Tenaya is working on three separate approaches (gene therapy, cell therapy and small molecule) to develop new treatments for heart disease.
In an audio interview from the recent ASCO-SITC meeting, Chen weighs in on comparisons of PD-1 and PD-L1 inhibitors, the IDO failures, biomarkers and his new work at the private biotech IGM Biosciences.
Executive reshuffle at Karyopharm Therapeutics, plus new chief financial officers at Redx Pharma and Vaccibody.